SLC5A2 and type 2 diabetes mellitus: The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Patients (EMPA-REG OUTCOMES) study reported that treatment with sodium–glucose cotransporter 2 (SGLT2) inhibitors, a novel class of hypoglycemic agents, reduced the rate of all-cause cardiovascular death in patients with T2DM at high risk of cardiovascular events [119].